{
  "documentMetadata": {
    "title": "Necrotizing Fasciitis, Staph. aureus",
    "lastUpdated": "2023-04-22",
    "sourceFile": "Necrotizing Fasciitis, Staph. aureus.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Skin infection due to community-acquired methicillin-resistant Staph. aureus (CA-MRSA).",
        "Infection extends into the fascial plane between muscle and subcutaneous fat with resulting necrotizing fasciitis."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staphylococcus aureus (CA-MRSA)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "procedure",
      "procedureData": {
        "name": "Incision for exploration, drainage and debridement"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          }
        ],
        "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator); alternative is trough of 15-20 µg/mL"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "procedure",
      "procedureData": {
        "name": "Incision for exploration, drainage and debridement"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Daptomycin",
            "dose": "4-6 mg/kg",
            "route": "IV",
            "frequency": "q24h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Telavancin",
            "dose": "10 mg/kg",
            "route": "IV",
            "frequency": "q24h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Linezolid",
            "dose": "600 mg",
            "route": "IV",
            "frequency": "q12h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Clindamycin",
            "dose": "900 mg",
            "route": "IV",
            "frequency": "q8h"
          }
        ],
        "notes": "is sometimes added to initial regimen as adjunct to inhibit protein (toxin) synthesis (which can occur if organism is susceptible; not needed if Linezolid is used as this is a protein synthesis inhibitor)."
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Empiric regimens should include gram-negative and anaerobic coverage in addition to the above, until pathogen identified. Then, switch to targeted therapy."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Historically, Staph. aureus was not associated with necrotizing fasciitis, but community-acquired MRSA is different and can cause the disease.",
        "See Necrotizing Fasciitis, Overview for further discussion and links to other etiologies.."
      ]
    }
  ]
}
